Intestinal Bacterial Composition to Block Drug-Resistant Colonization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for an effective antibacterial composition that can suppress the colonization and proliferation of drug-resistant bacteria and pro-inflammatory bacteria in the intestinal tract, which are associated with various diseases.
Innovation Solution
The development of an antibacterial composition containing specific intestinal bacteria strains, such as those identified by their 16S rDNA sequences, which can suppress the colonization of drug-resistant bacteria and pro-inflammatory bacteria, including strains like Kp2H7, by administering these strains to the intestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If antibiotic administration is performed to eliminate intestinal bacteria, then the intestinal tract becomes available for colonization by Th1 cell-inducible bacteria, but this leads to increased colonization of drug-resistant bacteria and pro-inflammatory bacteria
Solution Approach 1:
The patent applies preliminary anti-action by administering beneficial intestinal bacteria (such as Lactobacillus, Bifidobacterium, or other probiotic strains) before or concurrently with antibiotic treatment. These beneficial bacteria preemptively occupy ecological niches in the intestinal tract, preventing drug-resistant bacteria and pro-inflammatory bacteria from colonizing even when antibiotics eliminate the normal flora. This is demonstrated in the examples where probiotic administration suppressed the colonization of pathogenic bacteria despite antibiotic-induced flora disruption
Solution Approach 2:
The patent uses beneficial intestinal bacteria as an intermediary organism that mediates between the antibiotic treatment and the pathogenic bacteria. These intermediary bacteria interact with the intestinal environment and pathogenic organisms through competitive exclusion, production of antimicrobial substances, and modulation of the immune response, thereby preventing direct colonization of harmful bacteria while allowing the antibiotic therapy to proceed
2Adaptability or versatility
If oral bacteria colonize in the intestinal tract, then Th1 cells are induced and proliferate, but this leads to development of diseases such as Crohn's disease, liver cirrhosis, and colorectal cancer
Solution Approach 1:
The patent applies preliminary anti-action by introducing beneficial intestinal bacteria that preemptively prevent oral bacteria from colonizing the intestinal tract. These beneficial bacteria establish themselves in the intestinal ecosystem first, creating a protective barrier that blocks the colonization of Th1 cell-inducible oral bacteria, thereby preventing the downstream inflammatory response and disease development associated with such colonization
Solution Approach 2:
The patent converts the potential harm of bacterial colonization into a benefit by using beneficial bacteria to occupy the ecological niche that would otherwise be taken by harmful oral bacteria. The same colonization mechanism that causes disease when performed by oral bacteria is harnessed for protection when performed by probiotic strains, transforming the colonizable state of the intestinal tract from a vulnerability into a defense mechanism
3Ease of manufacture
If intestinal bacteria are eliminated by antibiotic administration, then the intestinal flora is disrupted, but this creates an opportunity for drug-resistant bacteria to colonize and proliferate
Solution Approach 1:
The patent applies preliminary anti-action by administering probiotic bacteria before or during antibiotic treatment to preemptively block the colonization of drug-resistant bacteria. While antibiotics eliminate competing intestinal bacteria, the probiotics are either resistant to the antibiotics or are administered in sufficient quantities to repopulate the intestinal tract rapidly, maintaining suppression of drug-resistant organisms throughout the treatment period
Solution Approach 2:
The patent applies preliminary action by pre-establishing a population of beneficial bacteria in the intestinal tract before antibiotic administration begins. This preliminary colonization ensures that when antibiotics disrupt the normal flora, the probiotic bacteria are already in position to prevent drug-resistant bacteria from establishing themselves, maintaining reliable suppression throughout the antibiotic treatment course
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides an antibacterial composition against drug-resistant bacteria or pro-inflammatory bacteria containing an intestinal bacterium as an active ingredient, or a pharmaceutical composition for treating, ameliorating, or preventing an infectious disease or an inflammatory disease.